WEBFeb 28, 2024 · Pharnext progresses in analyzing data from pivotal Phase III study of PXT3003 in Charcot-Marie-Tooth disease type 1A PARIS, France, February 28, 2024, 08:30 am CET – Pharnext SA (FR001400N1P4 - ALPHA) (the “Company”), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases